Muscular dystrophy (MD) is a group of genetic rare diseases ( with 50 + types) collectively impact on millions of individuals globally and  most of them are children. Currently, there is no effective and affordable treatment for any type of MDs. Most of MDs are associated with defects in dystrophin associated glycoproteins complex (DGC) that is key structure connect extracellular matrix protein such as laminins and agrin to cytoskeleton.   The key component of the DGC is dystroglycan that is the receptor of laminins and agrin.